Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Results 1 - 16 of 16

Recs

0
Member Avatar asilverp (30.47) Submitted: 8/29/2014 9:17:32 AM : Underperform Start Price: $7.35 FOLD Score: +2.31

Very high valuations + limited growth. They make drugs for orphan diseases. Unless they cure Parkinson's disease, we are looking at a terrible stock. Really noble kind of company though, if the valuations were (much) better, I would buy it. Good niche operation.

Recs

0
Member Avatar pchop12316 (85.46) Submitted: 8/26/2014 8:58:17 PM : Outperform Start Price: $6.20 FOLD Score: +15.83

More new highs to come

Recs

1
Member Avatar pchop123 (79.56) Submitted: 8/6/2014 4:48:06 PM : Outperform Start Price: $4.27 FOLD Score: +64.35

stay aboard this one

Recs

0
Member Avatar SkepBioInvestor (95.30) Submitted: 8/4/2014 4:32:40 PM : Outperform Start Price: $4.12 FOLD Score: +70.57

Positive migalastat ph3 data and potential regulatory filings

Recs

2
Member Avatar zzlangerhans (99.78) Submitted: 3/29/2014 2:32:27 PM : Outperform Start Price: $2.17 FOLD Score: +223.10

I've sort of given up on Amicus myself after following them for seven years and not seeing any signs of success or impending success in clinical trials of their small molecule "chaperones" for lysosomal storage diseases. In 2012 the company got slapped down from their latest stab at legitimacy with weak six month data from Study 011 phase III trial of migalastat for Fabry's disease. Twelve month data should have been released last June, but the company kept pushing the data release back and now they're saying they will release 12 and 24 month data together next quarter. Huh? Obviously the 12 month data are bad and they're hoping the 24 month data will bail them out.

I just need to register my skepticism before copping to the fact that I have 4000 shares with a cost basis of 2.33, mostly due to a recent buy of 3000 shares. Portefeuille likes to play Amicus and he's had great success to date, so I'm rolling with him on this one. In addition, topline 18 month data from a European phase III trial of migalastat is expected in H2 2014. If these trials fail, the market cap may slip under a buck as Amicus falls back on early stage trials of migalastat/ERT to maintain a raison d'etre.

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:22:55 PM : Underperform Start Price: $2.25 FOLD Score: -201.34

Short. Biopharma. Revs down. Issued a ton more stock to raise money.

Recs

0
Member Avatar jawdoc19 (< 20) Submitted: 1/5/2013 10:21:34 AM : Outperform Start Price: $3.80 FOLD Score: +51.60

On January 4th it was announced that Amicus "announced positive preliminary results from all four dose cohorts in a phase 2 study of its treatment for Pompe disease, a lysosomal storage disease characterized by progressive skeletal muscle weakness and respiratory insufficiency

Biopharmaceutical company, focuses on the development of pharmacological chaperone monotherapy programs and pharmacological chaperones in combination with enzyme replacement therapy, better known as ERT." Amicus is primarily focused on the development of the following three drug candidates, although there are several more under development: Migalastat HCI (a Phase 3 Phase III clinical trial for the treatment of Fabry disease), AT3375 (a preclinical stage for the treatment of Parkinson's disease) and AT2220 (a treatment co-administered with ERT for the treatment of patients diagnosed with Pompe disease).

Recs

3
Member Avatar rockjam78 (58.97) Submitted: 7/24/2012 3:27:21 AM : Outperform Start Price: $5.30 FOLD Score: -12.80

Glaxosmithkline just made a huge investment in this biotech firm.Could there be a blockbuster drug approval on the horizon? This is a total speculation play,but one that may pay off.Through the dice on this one.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:35:17 PM : Outperform Start Price: $6.32 FOLD Score: -32.84

Biotech

Recs

0
Member Avatar Drjohn08318 (< 20) Submitted: 1/12/2012 2:55:25 PM : Outperform Start Price: $4.14 FOLD Score: +18.45

Awesome company making great product; employees are happy, and I predict great things from them in the near future....

Recs

0
Member Avatar MATTALANKANE (35.69) Submitted: 7/13/2010 12:14:16 AM : Outperform Start Price: $2.07 FOLD Score: +163.46

IF THE COMPANY CAN BRANCH OUT THEIR PIPELINE AND OVERLAP WITH DUAL ALZHEIMERS USES FOR THEIR DRUGS................THAN WATCH OUT!!!!!!

Recs

1
Member Avatar mansloth (98.57) Submitted: 1/8/2009 8:32:13 PM : Outperform Start Price: $7.92 FOLD Score: -133.29

Therapeutics for protein folding diseases are going to be trendy over the next couple of years. More (and perhaps better) competitors with a focus on protein folding diseases will go public over the course of the next five years, while established ones like this will get gobbled up.

Recs

0
Member Avatar WordTickers (86.52) Submitted: 5/31/2008 12:19:40 PM : Outperform Start Price: $9.91 FOLD Score: -81.78

Testing out a portfolio with outperforms on stocks with tickers that spell words.

Recs

1
Member Avatar lw100 (< 20) Submitted: 5/14/2008 11:57:18 AM : Outperform Start Price: $10.28 FOLD Score: -76.98

Impressive pipeline. Great results

Recs

0
Member Avatar SanDieguito (< 20) Submitted: 12/20/2007 10:17:40 AM : Underperform Start Price: $9.99 FOLD Score: +72.30

down $5 to $10

Recs

1
Member Avatar ANALYST10 (91.51) Submitted: 7/9/2007 1:59:28 PM : Outperform Start Price: $12.16 FOLD Score: -78.83

Hearing & reading very positive reports on this relatively new (recent IPO)Pharma stock!

Great time to get on the ground-floor of a potential ground-breaking pharmaceutical opportunity.

Should be be hearing good reports from analysts very soon, which will be stock/eye popping time.

Results 1 - 16 of 16

Featured Broker Partners


Advertisement